It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The mechanisms underlying the selective regional vulnerability to neurodegeneration in Huntington’s disease (HD) have not been fully defined. To explore the role of astrocytes in this phenomenon, we used single-nucleus and bulk RNAseq, lipidomics, HTT gene CAG repeat-length measurements, and multiplexed immunofluorescence on HD and control post-mortem brains. We identified genes that correlated with CAG repeat length, which were enriched in astrocyte genes, and lipidomic signatures that implicated poly-unsaturated fatty acids in sensitizing neurons to cell death. Because astrocytes play essential roles in lipid metabolism, we explored the heterogeneity of astrocytic states in both protoplasmic and fibrous-like (CD44+) astrocytes. Significantly, one protoplasmic astrocyte state showed high levels of metallothioneins and was correlated with the selective vulnerability of distinct striatal neuronal populations. When modeled in vitro, this state improved the viability of HD-patient-derived spiny projection neurons. Our findings uncover key roles of astrocytic states in protecting against neurodegeneration in HD.
Huntington’s disease (HD) is a neurodegenerative disease that shows selective regional vulnerability. Here, the authors show that postmortem brain HD astrocytes are regionally diverse, with a striatal disease-associated state and a cortical compensatory state that mitigated neural death.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Columbia University Irving Medical Center, Department of Neurology, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675)
2 Department of Developmental Biology Washington University School of Medicine in St. Louis, St. Louis, USA (GRID:grid.262962.b) (ISNI:0000 0004 1936 9342)
3 Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786)
4 Columbia University Irving Medical Center, Department of Pathology and Cell Biology, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675)
5 Northwestern University, Northwestern Feinberg School of Medicine, Evanston, USA (GRID:grid.16753.36) (ISNI:0000 0001 2299 3507)
6 New York Genome Center, New York, USA (GRID:grid.429884.b) (ISNI:0000 0004 1791 0895)
7 Columbia University Irving Medical Center, Department of Pathology and Cell Biology, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, New York, USA (GRID:grid.239585.0)
8 Columbia University Irving Medical Center, Department of Neurology, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, New York, USA (GRID:grid.239585.0)